Last Updated : April 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Viread | Tenofovir disoproxil fumarate | HIV infection | Do not list | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
| Viread | Tenofovir disoproxil fumarate | HIV infection | N/A | Complete | ||
| Viread | Tenofovir disoproxil fumarate | Hepatitis B (chronic) | List with clinical criteria and/or conditions | Complete | ||
| Visanne | Dienogest | Pain, pelvic pain associated with endometriosis | List with clinical criteria and/or conditions | Complete | ||
| Vitrakvi | Larotrectinib | NTRKplus solid tumours | Do not reimburse | Complete | ||
| Vitrakvi | larotrectinib | Solid tumours with NTRK gene fusion | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vizimpro | Dacomitinib | Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Vocabria and Cabenuva | cabotegravir sodium cabotegravir-rilpivirine | HIV-1 infection | Reimburse with clinical criteria and/or conditions | Complete | ||
| Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete |
Last Updated : April 20, 2024